X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
XVR012 is a cocktail of XVR013m and XVR014, targets three distinct epitopes. It is currently being evaluated in preclinical studies for the treatment of Covid-19 infection.
Lead Product(s): XVR013m,XVR014
Therapeutic Area: Infections and Infectious Diseases Product Name: XVR012
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 15, 2024
Details:
The funding will be used by ExeVir for pre-clinical research towards prophylactic and therapeutic solutions including, XVR021 for dengue by leveraging its unique, modular llama-derived antibody (VHH) technology platform to generate multi-specific antibodies.
Lead Product(s): XVR021
Therapeutic Area: Infections and Infectious Diseases Product Name: XVR021
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Flanders Innovation & Entrepreneurship
Deal Size: $1.7 million Upfront Cash: Undisclosed
Deal Type: Funding June 28, 2023
Details:
XVR013 targets a conserved region in the spike S2 subunit that is essential for viral entry. It neutralizes all previous and current variants of concern and the currently most frequently circulating variants, including XBB, XBB.1.5, BQ.1.1 and BF.7.
Lead Product(s): XVR013
Therapeutic Area: Infections and Infectious Diseases Product Name: XVR013
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: VIB
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 13, 2023
Details:
The EIB financing will help to advance ExeVir’s lead asset, XVR012, into clinical trials for COVID-19. XVR012, is a potent COVID-19 neutralizing antibody that targets the S1 and S2 region of the coronavirus.
Lead Product(s): XVR012
Therapeutic Area: Infections and Infectious Diseases Product Name: XVR012
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: European Investment Bank
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing January 09, 2023
Details:
Unique llama-derived VHH72-Fc antibody (XVR011) for potential treatment and prevention of Covid-19, ready to start first-in-human trials.
Lead Product(s): VHH72-Fc antibody
Therapeutic Area: Infections and Infectious Diseases Product Name: XVR011
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: VIB
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing March 16, 2021
Details:
Lead asset VHH72-Fc binds to a unique epitope that is conserved in SARS-CoV-1 and SARS-CoV-2 viruses and this binding prevents these viruses from entering the cell.
Lead Product(s): VHH72-FC,Ad26.COV2-S
Therapeutic Area: Infections and Infectious Diseases Product Name: VHH72-FC
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $27.1 million Upfront Cash: Undisclosed
Deal Type: Series A Financing May 28, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
